Answers are grounded in this paper and cite their sources.
Silver nanoparticles (Hematite (α-Fe2O3) have been used as an antimicrobial and as disinfectant. Nevertheless, there is limited data about its antitumor potential. This study focused on investigating the cytotoxic effects of Hematite (α-Fe2O3) from Butea monosperma flower extract on MCF-7 breast cancer cells and its mechanism of action. Green method was created for the synthesis of Hematite (α-Fe2O3) using an aqueous extract of B. monosperma flower. Synthesis of hematite (α-Fe2O3) was described by different analytical techniques including ultraviolet-visible spectrophotometer, field-emission scanning electron microscopy, X-ray diffraction, and Fourier transforms infrared spectroscopy. Cell viability was determined by the 3-[4, 5-dimethylthiazol-2-yl]-a 2,5-diphenyltetrazolium bromide assay. Reactive oxygen species (ROS) formation was measured using probe 2',7'-dichlorofluorescein diacetate and intracellular calcium (Cai2+) was evaluated with probe flu3-AM. Cells were treated with different concentrations of hematite (α-Fe2O3) (1, 3, 6, 10, 15, 25, 50 and 100 μg/mL). The results showed that hematite (α-Fe2O3) hindered cell growth in a dose-dependent manner. Hematite (α-Fe2O3) appeared to have dose-dependent cytotoxicity against MCF-7 cells through activation of the ROS generation and an increase in the intracellular Cai2+ (IC50 52 ± 3.14). In conclusion, the results of this preliminary study demonstrated that hematite (α-Fe2O3) from B. monosperma flower extract may be a potential therapeutic potential medicament for human breast cancer treatment.
No takes yet. Share an insight, caveat, or question.
Behera et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: